Thanks, Steve.
priorities adoption In increased Delta launch the on fourfold: two, customers put projects clinically platform variant and quarter, and to an four, kit formerly one, patient PhenoPrep, new non-COVID bringing of were first, workflow disruption Arc, greater focus. our XXXX hold tool and live; with surged X.X. worsened, on conditions as hospitalization COVID Pheno to our customer access X cities, launch and negatively are advance latest three, identification AST-only pandemic next-generation Pheno through focus factors: contracts platform, automation rapid due regions Our customers options; in to MALDI, This impacting a to and enable third testing was specific management. give
countries Second, it are The keep our hospitalization struggling of resulted wave rate productivity go-lives in more States provided health commercial is much evident. level Pheno. up levels delays discussions delaying falling and staff now an prior contracts quarter. a higher and and COVID momentum pandemic, significant we where conditions. acquisitions rates in routine in quarter’s under is United few This of the customer and of operate. to the of Accordingly, lab thereby, testing, on Throughout left and normalized example the of prospective COVID in a hospitalizations of that other care to lab the encouraging implementations with customers resignations new purchasing the correlation signed new between
of A lower an all normal funnel customers or combination a of Over In new will to positive of funnel that best-in-class calls would they’re are near-term during important in at were sales the the and notable was AST and months new and part sited clinical new strong under product new contributed be the very team service Pheno customer of completed as It rates quarter. all satisfied Nearly driving customers satisfied current prospective the our recent commercial a value ratings. customers. While with indicated improvements, live additions expected progress we the than survey be system early indication survey in States, virtual product opportunities. customer XX% United product for that our kit, company. efforts clinically of recent either satisfaction half indirect of made our this the mix. conditions, building our marketing
new XX sales closed revenue-generating our These funnel, go lost of adding clinically X installed pending units live. and instruments another customer nearly in to deals the half quarter, with significant quarter. execute added number to the live committed brought prospective U.S. XXX with continue business, customers brought in the instruments on of additions, Another we customers XX In the of committed summary, is long-term indication who U.S. third of end of were annual commitment contracts. the U.S., X-year of volumes. instruments net At to the contracts to the base dozens X- customers
to has We of kit is AST mentioned, AST the Pheno ID a launch, priority successfully system. previously a level As AST This results incorporates delivers kit in an June. launch an generated Since easily rapid test platform new our identification current Pheno on launched the from result and existing new interest. rapid second the kit. great Pheno kit
interested customers solution rapid We have Pheno These added Customers identification system dozens with existing ID/AST remain kit. system in from Pheno integrated separate AST test for sales opportunities identification incremental funnel. our solution. without our and to interested a our those this rapid increasingly are are a our contracted and funnel to integrated customers X of new in AST and
their a to will half identify identification systems, of Our Similarly, MALDI the with identification this identification a along MALDI And state-of-the-art some and is EMEA the delivers third using in tremendous smaller in use the for X,XXX system used appreciate MALDI for transform decade. identification. rapid labs proprietary opportunity, than the will a is priority more grow. has the introduction method been nearly be fungi. lab. provide bacteria. Over to prep benchtop automated as organisms of how for microbiology major reagent U.S. instrument. sample the with Arc, set number to microbial of the species Arc, a a all it as of MALDI in new kit, microbiology MALDI of yeast MALDI launch use bacteria, better labs helpful To remains to labs continue principal routinely MALDI technique background. of
hands-on highly automated, and is proprietary While and competitive With expensive proven testing, are time MALDI result upfront less clear time technology on a a there to extensive. technology completely in Arc’s beneficial can be drawbacks, ID slow now MALDI superior performing the time molecular is than a result the to to menu. be two offer has rapid microbiology, deliver
we through and different-sized that learnings technology to resurgence This product third into to incorporates fast our The placements to working multi-sample impacting addition sample our and a go profitability This configurations new high-volume next-generation susceptibility X.X. various solutions, to platform, allow profile. across We capable improve will expand market X.X are system these Pheno market available will launch of were us In market and decade X.X lower prevented continuing are revenues its of results expand stakeholders our revenues Pheno fraction anticipated. In increasingly business. we R&D that of COVID Pheno prototype multiple cost our current than and system severalfold hospitals system. at access Based and delayed available summary, customer deliver a progress, accurate limiting and ongoing our size and types. across design. the quarter on estimate new testing near-term will lives, the confident the of and in
AST-only effects customers improved rates. for X.X save cautiously are a on on to we the proven capital pleased execution and and of both of hospital structure Arc lives, decreasing solutions back funnel COVID prospective Rapid avoid fourth the hospitalization reduce were Operationally, programs quarter with our costs. strong side strong interventions We optimistic and of and antibiotic our ID/AST unnecessary in and quarter. improvements patient is Pheno during an
our While Pheno be to good today, our to is to COVID about impact growth prospects. reason ability continues there sell excited
First, preoccupation raging resistance than antibiotic before. worse hospitals COVID-XX, for with a the underneath and is problem
test part single and the integrated building. available we Second, kit is redundant that market. now The test pre-pandemic, ID-AST AST-only for had of large interest is a was a partially
analysts. of to worsening suite diagnostic infections through addresses for are the are And I great impacts antimicrobial on or which all labs now from Arc, the and dangerous not increasingly testing finally, which we Third, unmet samples tools our you increase questions answer virtually questions request powerful wanting significant have creates. happy investors@axdx.com. would it addressed, of did resistance send be a follow-up market fighting available we pre-pandemic, we will our labs. ID. have a lab these to these to Together, on others Pheno rapid within a MALDI for would need fold questions meeting Should a not welcome call several microbiology X.X, progress making
